You are here

  • Home
  • Archive
  • Volume 12, Issue 4
  • Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial

Article metrics

Article menu
Oncology
Protocol
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial

 

Online download statistics by month:

Online download statistics by month: April 2022 to September 2024

AbstractFullPdf
Apr 2022999997149
May 202215815656
Jun 202211611037
Jul 202215615844
Aug 202210410423
Sep 2022686429
Oct 2022454527
Nov 2022716538
Dec 2022494718
Jan 2023605016
Feb 2023484525
Mar 2023393813
Apr 2023252623
May 2023343416
Jun 2023302710
Jul 2023212011
Aug 2023525025
Sep 2023585914
Oct 2023363621
Nov 2023474814
Dec 2023686020
Jan 2024343169
Feb 2024353417
Mar 2024333022
Apr 2024252424
May 2024383525
Jun 2024252214
Jul 2024403731
Aug 2024292729
Sep 2024222020
Total25652499880